» Articles » PMID: 27239062

Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer Skills

Overview
Date 2016 May 31
PMID 27239062
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Because of the often unfavorable prognosis, particularly for patients with metastases, health-related quality of life is extremely important for breast cancer patients. In recent years, data on patient-relevant endpoints is being increasingly collected electronically; however, knowledge on the acceptance and practicability of, and barriers to, this form of data collection remains limited. A questionnaire was completed by 96 patients to determine to what extent existing computer skills, disease status, health-related quality of life and sociodemographic factors affect patients' potential willingness to use electronics methods of data collection (ePRO). 52 of 96 (55 %) patients reported a priori that they could envisage using ePRO. Patients who a priori preferred a paper-based survey (pPRO) tended to be older (ePRO 53 years vs. pPRO 62 years; p = 0.0014) and typically had lower levels of education (p = 0.0002), were in poorer health (p = 0.0327) and had fewer computer skills (p = 0.0003). Barriers to the prospective use of ePRO were identified in older patients and patients with a lower quality of life. Given the appropriate conditions with regard to age, education and current health status, opportunities to participate should be provided to encourage patients' willingness to take part and ensure the validity of survey results. Focusing on ease of use of ePRO applications and making applications more patient-oriented and straightforward appears to be the way forward.

Citing Articles

Advancing patient-centered cancer care: a systematic review of electronic patient-reported outcome measures.

Salmani H, Nasiri S, Alemrajabi M, Ahmadi M Front Rehabil Sci. 2024; 5:1427712.

PMID: 39386354 PMC: 11461464. DOI: 10.3389/fresc.2024.1427712.


The advantages, disadvantages, threats, and opportunities of electronic patient-reported outcome systems in cancer: A systematic review.

Salmani H, Nasiri S, Ahmadi M Digit Health. 2024; 10:20552076241257146.

PMID: 38812853 PMC: 11135117. DOI: 10.1177/20552076241257146.


Longitudinal assessment of real-world patient adherence: a 12-month electronic patient-reported outcomes follow-up of women with early breast cancer undergoing treatment.

Gebert P, Hage A, Blohmer J, Roehle R, Karsten M Support Care Cancer. 2024; 32(6):344.

PMID: 38740611 PMC: 11090970. DOI: 10.1007/s00520-024-08547-7.


Health status based on EQ-5D-5L for the cancer patient population in Malaysia.

Wan Puteh S, Razali H, Ismail A, Zulkifli M Sci Rep. 2024; 14(1):8152.

PMID: 38589488 PMC: 11001969. DOI: 10.1038/s41598-024-58844-8.


Patient-targeted education (ePRO-E) to increase ePRO intent within an Alliance clinical trial (A221805-SI1).

Smith E, Cho Y, Hillman S, Scott M, Harlos E, Wills R JNCI Cancer Spectr. 2024; 8(1).

PMID: 38230706 PMC: 10868392. DOI: 10.1093/jncics/pkae002.


References
1.
Abernethy A, Zafar S, Uronis H, Wheeler J, Coan A, Rowe K . Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients. J Pain Symptom Manage. 2010; 40(4):545-58. DOI: 10.1016/j.jpainsymman.2010.01.017. View

2.
Wintner L, Giesinger J, Kemmler G, Sztankay M, Oberguggenberger A, Gamper E . [The benefits of using patient-reported outcomes in cancer treatment: an overview]. Wien Klin Wochenschr. 2012; 124(9-10):293-303. DOI: 10.1007/s00508-012-0168-3. View

3.
Smith I . Goals of Treatment for Patients with Metastatic Breast Cancer. Semin Oncol. 2006; 33(Suppl 2):S2-5. DOI: 10.1053/j.seminoncol.2005.07.030. View

4.
Cetin K, Christiansen C, Svaerke C, Jacobsen J, Sorensen H . Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval. BMJ Open. 2015; 5(4):e007702. PMC: 4420974. DOI: 10.1136/bmjopen-2015-007702. View

5.
Lipscomb J, Reeve B, Clauser S, Abrams J, Bruner D, Burke L . Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol. 2007; 25(32):5133-40. DOI: 10.1200/JCO.2007.12.4644. View